{"id":"W2767214300","doi":"10.1093/neuonc/nox168.247","title":"DDIS-11. TTI-2341: A NOVEL, ORALLY BIOAVAILABLE, BRAIN-PENETRANT, COVALENT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM) AND BRAIN METASTASES OF NON-SMALL CELL LUNG CANCER (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Erlotinib; Afatinib; Epidermal growth factor receptor; Pharmacology; Bioavailability; EGFR inhibitors; Blood–brain barrier; Cancer research; Gefitinib; Medicine; Cancer; Central nervous system; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001020207,0.0005206264,0.000354695,0.000328829,0.0001835651,0.0002721305,0.000320476,0.0003974169,0.001600598],"category_scores_gemma":[0.00009003074,0.0001442131,0.0002541082,0.0003530735,0.0001722014,0.0002346583,0.0002058937,0.0006264768,0.0007376279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006239589,"about_ca_system_score_gemma":0.0005015819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001104325,"about_ca_topic_score_gemma":0.002389752,"domain_scores_codex":[0.999897,0.00001033071,0.00000912295,0.00002605085,0.00003642056,0.00002097721],"domain_scores_gemma":[0.9999783,0.00000194735,0.000007631153,0.000001469539,0.000003590425,0.000007132043],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001132643,0.0004163854,0.0009803645,0.001034644,0.00005798807,0.0009784647,0.00007190666,0.001435839,0.867855,0.001490838,0.00509945,0.1194465],"study_design_scores_gemma":[0.0005273872,0.004025333,0.004862273,0.00003540871,0.0001019439,0.006448537,0.00002860907,0.001710303,0.9147852,0.000250477,0.06718571,0.0000386881],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8912832,0.05334811,0.01655096,0.001317537,0.000609018,0.0007482222,0.006659724,0.0009738626,0.02850939],"genre_scores_gemma":[0.9427106,0.02018666,0.006106755,0.000362123,0.00007403414,0.0002018415,0.006122791,0.00004138283,0.02419386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001600598,"threshold_uncertainty_score":0.005354524,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03715621773001542,"score_gpt":0.3461400694882206,"score_spread":0.3089838517582051,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}